ElizabethKeatingO'DonnellMD

Oncology • Boston, MA

Hematologic Oncology

Assistant Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School

Join to view full profile

Dr. O'Donnell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. O'Donnell's full profile

Already have an account?

Office
450 Brookline Ave
Boston, MA 02215
Phone+1 617-632-3000
Is this information wrong?

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2010 - 2014
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2007 - 2010
Vanderbilt University School of MedicineClass of 2007

Certifications & Licensure

MA State Medical License 2009 - 2025
ME State Medical License 2020 - 2021
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing Start of enrollment: 2016 Jan 01
Completed
Phase 2

Publications & Presentations

PubMed

1 citations
Oncologist perspective: role of imaging in myeloma.
Yael N Shapiro, Elizabeth O'Donnell> ;Skeletal Radiology. 2022 Jan 1
10 citations
Lifestyle considerations in multiple myeloma
Yael N Shapiro, Jeffrey Peppercorn, Andrew Yee, Andrew R. Branagan, Noopur Raje, Elizabeth K O' Donnell> ;Blood Cancer Journal. 2021 Oct 26
40 citations
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia.
Jorge J. Castillo, Kirsten Meid, Joshua Gustine, Carly Leventoff, Timothy P White, Catherine A Flynn, Shayna Sarosiek, Maria Demos, Maria Luisa Guerrera, Amanda Kofide...> ;Leukemia. 2021 Sep 16
23 citations
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.
Kenneth C. Anderson, Daniel Auclair, Stacey J Adam, Amit Agarwal, Melissa Anderson, Hervé Avet-Loiseau, Mark Bustoros, Jessica R. Chapman, Dana E. Connors, Ajeeta B Da...> ;Clinical Cancer Research. 2021 Jul 28
534 citations
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CART...
Jesus G. Berdeja, Deepu Madduri, Saad Z. Usmani, Andrzej Jakubowiak, Mounzer Agha, Adam D. Cohen, A. Keith Stewart, Parameswaran Hari, Myo Htut, Alexander M. Lesokhin,...> ;Lancet. 2021 Jul 24
25 citations
The dynamics of human bone marrow adipose tissue in response to feeding and fasting
Pouneh K. Fazeli, Miriam A. Bredella, Olga Gisela Pachon-Peña, Wenxiu Zhao, Xun Zhang, Alexander T. Faje, Sai P. Polineni, Tara M. Holmes, Hang Lee, Elizabeth O'Donnel...> ;JCI Insight. 2021 Jun 22
1 citations
Induction Therapy Strategies in the Transplant-Ineligible Population.
Narsis Attar, Elizabeth O'Donnell> ;Cancer Journal. 2021 May 1
Case 3-2021: A 48-Year-Old Man with Transient Vision Loss.
Sebastian Unizony, Hillary R. Kelly, Elizabeth O'Donnell, Sam Sadigh> ;The New England Journal of Medicine. 2021 Jan 28
61 citations
Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma.
Shruti Gupta, Harish Seethapathy, Ian A. Strohbehn, Matthew J. Frigault, Elizabeth O'Donnell, Caron A. Jacobson, Shveta S. Motwani, Samir M. Parikh, Gary C. Curhan, Ke...> ;American Journal of Kidney Diseases. 2020 Jul 1
10 citations
Moving forward on all fronts: impact, patterns, and barriers to exercise in cancer survivors and patients living with advanced disease
Sasha E. Knowlton, Elizabeth O'Donnell, Nora Horick, Giselle K. Perez, Elyse R. Park, Julia Rabin, Kit M. Quain, Jessica Garton, Jeffrey Peppercorn> ;Supportive Care in Cancer. 2020 Feb 7
11 citations
Value of low-dose whole-body CT in the management of patients with multiple myeloma and precursor states.
F. Joseph Simeone, Joel P Harvey, Andrew Yee, Elizabeth O'Donnell, Noopur Raje, Martin Torriani, Miriam A. Bredella> ;Skeletal Radiology. 2019 May 1
2 citations
Body Mass Index and Outcomes in Germ-Cell Tumors.
Bradley Alexander McGregor, Rowan Miller, Elizabeth O'Donnell, Laurence Albiges, Christopher Sweeney, Sarah C. Markt> ;Clinical Genitourinary Cancer. 2019 Apr 25
4 citations
Initiation and interruption in intravenous bisphosphonate therapy among patients with multiple myeloma in the United States.
Leah J. McGrath, Rohini K. Hernandez, Robert A. Overman, Diane Reams, Alexander Liede, M Alan Brookhart, Elizabeth O'Donnell> ;Cancer Medicine. 2019 Jan 1
29 citations
Ixazomib for the treatment of multiple myeloma
Paul G. Richardson, Sonja Zweegman, Elizabeth O'Donnell, Jacob P. Laubach, Noopur Raje, Peter M. Voorhees, Renda H. Ferrari, Tomas Skacel, Shaji Kumar, Sagar Lonial> ;Expert Opinion on Pharmacotherapy. 2018 Nov 13
101 citations
A Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone in Transplant-Ineligible Multiple Myeloma
Elizabeth O'Donnell, Jacob P. Laubach, Andrew Yee, Tianqi Chen, Carol Ann Huff, Frank G. Basile, Philip M. Wade, Claudia E. Paba-Prada, Irene M. Ghobrial, Robert L. Sc...> ;British Journal of Haematology. 2018 Jul 1
39 citations
Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing.
Guangwu Guo, Noopur Raje, Charles Seifer, Jake A. Kloeber, Randi Isenhart, Gavin Ha, Andrew Yee, Elizabeth O'Donnell, Yu-Tzu Tai, Paul G. Richardson, Giada Bianchi, Ja...> ;Leukemia. 2018 Mar 27
235 citations
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
Shaji Kumar, Meletios A. Dimopoulos, E Kastritis, Evangelos Terpos, Hareth Nahi, H. Goldschmidt, Jens Hillengass, Xavier Leleu, Meral Beksac, Melissa Alsina, Albert Or...> ;Leukemia. 2017 May 12
25 citations
Myeloma bone disease: pathogenesis and treatment.
Elizabeth O'Donnell, Noopur Raje> ;Clinical Advances in Hematology & Oncology. 2017 Apr 1
14 citations
New monoclonal antibodies on the horizon in multiple myeloma.
Elizabeth O'Donnell, Noopur Raje> ;Therapeutic Advances in Hematology. 2017 Feb 1
122 citations
Genomic evolution and chemoresistance in germ-cell tumours
Amaro Taylor-Weiner, Travis I. Zack, Elizabeth O'Donnell, Jennifer L. Guerriero, Brandon Bernard, Anita Reddy, G. Celine Han, Saud H. AlDubayan, Ali Amin-Mansour, Stev...> ;Nature. 2016 Dec 1
10 citations
Age ≥40 Years Is Associated with Adverse Outcome in Metastatic Germ Cell Cancer Despite Appropriate Intended Chemotherapy
Rowan E. Miller, Sarah C. Markt, Elizabeth O'Donnell, Brandon Bernard, Laurence Albiges, Clair J. Beard, Christopher Sweeney> ;European Urology Focus. 2016 Oct 26
21 citations
Abdominal adipose tissue in MGUS and multiple myeloma.
Joyce V. Veld, Elizabeth O'Donnell, Michaela R. Reagan, Andrew Yee, Martin Torriani, Clifford J. Rosen, Miriam A. Bredella> ;Skeletal Radiology. 2016 Jun 25
8 citations
Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach
Clair J. Beard, Shilpa Gupta, Robert J. Motzer, Elizabeth O'Donnell, Elizabeth R. Plimack, Kim Margolin, Charles J. Ryan, Joel Sheinfeld, Darren R. Feldman> ;Journal of the National Comprehensive Cancer Network. 2015 Jun 1
53 citations
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide–bortezomib combinations
Cindy Varga, Wanling Xie, Jacob P. Laubach, Irene M. Ghobrial, Elizabeth O'Donnell, Matthew Weinstock, Claudia E. Paba-Prada, Diane Warren, Michelle E. Maglio, Robert ...> ;British Journal of Haematology. 2015 Jun 1
79 citations
Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
Yuko Mishima, Loredana Santo, Homare Eda, Diana Cirstea, Neeharika Nemani, Andrew Yee, Elizabeth O'Donnell, Martin K. Selig, Steven N. Quayle, Shirin Arastu-Kapur, Chr...> ;British Journal of Haematology. 2015 May 1
Join now to see all

Abstracts/Posters

Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma
Elizabeth K. O'Donnell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Elizabeth K. O'Donnell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy
Elizabeth K. O'Donnell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019